Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with ۵-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial
- سال انتشار: 1390
- محل انتشار: مجله سرطان خاورمیانه، دوره: 2، شماره: 2
- کد COI اختصاصی: JR_MISJ-2-2_002
- زبان مقاله: انگلیسی
- تعداد مشاهده: 192
نویسندگان
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: The present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (TAC) vs. ۵-fluorouracil, doxorubicin and cyclophosphamide (FAC) as neoadjuvant chemotherapy in women with locally advanced breast cancer. Methods: One hundred women with pathologically confirmed newly diagnosed locally advanced (T۳-T۴ or N۲-N۳) breast cancer were randomly assigned to receive a median of four cycles of either ۵-fluorouracil (۶۰۰ mg/m۲), doxorubicin (۶۰ mg/m۲) and cyclophosphamide (۶۰۰ mg/m۲) every three weeks or docetaxel (۷۵ mg/m۲), doxorubicin (۵۰ mg/m۲) and cyclophosphamide (۵۰۰ mg/m۲) every three weeks followed by modified radical mastectomy. Complete clinical and pathologic response rates and toxicity were the primary and secondary outcome measures of the study.Results: Median age for all patients was ۴۳.۴ years (range ۲۵-۶۳ years). Patients in the TAC arm achieved a higher clinical (۱۶%) response rate than those in the FAC arm (۴%, P=۰.۰۴۶). The pathologic response rate was also higher in the TAC arm compared to the FAC arm [TAC (۲۰%) vs. FAC (۶%), P=۰.۰۳۷]. Estrogen receptor- negative status correlated with a higher clinical [TAC (۱۹%) vs. FAC (۴%), P=۰.۰۳۲] and pathologic [TAC (۲۳%) vs. FAC (۴%), P=۰.۰۱۱)] response rate in both arms. All patients generally tolerated treatment well, and treatment-related toxicities were manageable.Conclusion: Combined treatment with TAC led to higher rates of complete clinical and pathologic response with acceptable toxicity compared to FAC in patients with locally advanced breast cancer. However, further follow-up is needed to translate this response into improvements in survival.کلیدواژه ها
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.